Clinical Trial

A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101. Participants will have their own T cells modified in a laboratory and given back to them as OPB-101 in this one-time treatment. Participants will be in the hospital when they receive OPB-101 and then be checked at the clinical site frequently for the first few months.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-06-20; most recent amendment 2025-12-11.
Status change: Not Yet Recruiting → Recruiting 2025-06-30
Trial Details
NCT Number NCT07030907
Lead Sponsor Outpace Bio, Inc.
Conditions Ovarian Cancer Recurrent, Ovarian Cancer, Platinum Resistant Ovarian Cancer
Enrollment 30 participants
Start Date 2025-06-16
Primary Completion 2028-05-15 (estimated)
Study Completion 2030-05-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-18